<scp>ADAPT NXT</scp>: Fixed Cycles or Every‐Other‐Week <scp>IV</scp> Efgartigimod in Generalized Myasthenia Gravis
Efgartigimod administered as either fixed cycles or Q2W dosing results in rapid, robust, and sustained clinically meaningful improvement. These results build upon previous studies and provide additional efgartigimod dosing approaches to achieve and sustain clinical efficacy in patients with gMG.
Authors
- Elena Cortés‐Vicente (ORCID: https://orcid.org/0000-0002-1428-1072)
- Deborah Gelinas
- Edward Brauer
- Renato Mantegazza (ORCID: https://orcid.org/0000-0002-9810-5737)
- Kelly Gwathmey (ORCID: https://orcid.org/0000-0002-7589-8826)
- Kristl G. Claeys (ORCID: https://orcid.org/0000-0001-9937-443X)
- Anne Sumbul
- Andreas Meisel (ORCID: https://orcid.org/0000-0001-7233-5342)
- Gregory Sahagian (ORCID: https://orcid.org/0000-0002-3893-4920)
- Vera Bril (ORCID: https://orcid.org/0000-0002-5805-4883)
- Shahram Attarian (ORCID: https://orcid.org/0000-0002-7211-4694)
- Ali A. Habib (ORCID: https://orcid.org/0000-0003-3432-9747)
- Delphine Masschaele
- Daniela Hristova
- Yessar Hussain
- Rosa H. Jimenez
Institutions
- University Health Network (CA)
- Virginia Commonwealth University (US)
- University of Toronto (CA)
- University of California, Irvine (US)
- Hospital de Sant Pau (ES)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Centro de Investigación Biomédica en Red (ES)
- Neurology Center of Southern California (US)
- Texas Neurology (US)
- Argenx (Belgium) (BE)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Charité - Universitätsmedizin Berlin (DE)
- KU Leuven (BE)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1002/acn3.70051
- Citations
- 9
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 12.50
Funders
- Amgen
- Pfizer
- Sanofi
- Biogen
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- CSL Behring
- Regeneron Pharmaceuticals
- Amicus Therapeutics
- Argenx
- Ipsen
- Grifols
- Genentech
- UCB Pharma